Boundless Bio, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

BOLD$2.45-0.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Stockholders’ Equity

(in thousands)

Common Stock · Additionalpaid-in · Accumulatedother comprehensive · Accumulated · Total stockholders'
	Shares	Amount	capital	income/ (loss)	deficit	equity
Balance at December 31, 2025	22,407	$2	$358,257	$64	$(259,669)	$98,654
Stock-based compensation	—	—	1,371	—	—	1,371
Unrealized loss on short-term investments	—	—	—	(87)	—	(87)
Net loss	—	—	—	—	(13,555)	(13,555)
Balance at March 31, 2026	22,407	$2	$359,628	$(23)	$(273,224)	$86,383
Stock-based compensation	—	—	3,222	—	—	3,222
Issuance of common stock under the Employee Stock Purchase Plan	35	—	37	—	—	37
Exercise of stock options	33	—	36	—	—	36
Unrealized loss on short-term investments	—	—	—	(9)	—	(9)
Net loss	—	—	—	—	(23,693)	(23,693)
Balance at June 30, 2026	22,475	$2	$362,923	$(32)	$(296,917)	$65,976
Stock-based compensation	—	—	284	—	—	284
Exercise of stock options	634	—	813	—	—	813
Unrealized gain on short-term investments	—	—	—	13	—	13
Net loss	—	—	—	—	(5,364)	(5,364)
Balance at September 30, 2026	23,109	$2	$364,020	$(19)	$(302,281)	$61,722
Balance at December 31, 2024	22,300	$2	$351,991	$121	$(201,472)	$150,642
Stock-based compensation	—	—	1,797	—	—	1,797
Unrealized loss on short-term investments	—	—	—	(89)	—	(89)
Net loss	—	—	—	—	(15,758)	(15,758)
Balance at March 31, 2025	22,300	$2	$353,788	$32	$(217,230)	$136,592
Stock-based compensation	—	—	1,693	—	—	1,693
Issuance of common stock under the Employee Stock Purchase Plan	86	—	117	—	—	117
Unrealized loss on short-term investments	—	—	—	(36)	—	(36)
Net loss	—	—	—	—	(15,675)	(15,675)
Balance at June 30, 2025	22,386	$2	$355,598	$(4)	$(232,905)	$122,691
Stock-based compensation	—	—	1,303	—	—	1,303
Issuance of common stock under the Employee Stock Purchase Plan	—	—	—	—	—	—
Unrealized gain on short-term investments	—	—	—	54	—	54
Net loss	—	—	—	—	(13,879)	(13,879)
Balance at September 30, 2025	22,386	$2	$356,901	$50	$(246,784)	$110,169

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.